Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 6/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | GPR174 | Q9BXC1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29179883 | 0.89 | ALDH1A1 (0.39) | CSF1RPOLBCYP2C9CYP2C19MAPT | |
| SCHEMBL28995471 | 0.86 | FFAR4 (0.53) | POLBCYP2C9CYP2C19MAPTTDP1 | |
| SCHEMBL3201980 | 0.83 | ALDH1A1 (0.59) | CSF1RPOLBMAPTTDP1ALDH1A1 | |
| SCHEMBL29772056 | 0.83 | ALDH1A1 (0.59) | CSF1RPOLBMAPTTDP1ALDH1A1 | |
| SCHEMBL25175403 | 0.83 | FFAR4 (0.52) | FFAR4 | |
| SCHEMBL25196247 | 0.79 | POLB (0.41) | POLBCYP2C9CYP2C19MAPTTDP1 | |
| SCHEMBL19510979 | 0.79 | MAPT (0.45) | MAPTTDP1FFAR4 | |
| SCHEMBL27098837 | 0.79 | FFAR4 (0.41) | FFAR4ACHE | |
| SCHEMBL27098835 | 0.79 | TYMP (0.42) | FFAR4ACHE | |
| SCHEMBL25172775 | 0.78 | FFAR4 (0.45) | MAPTTDP1FFAR4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | CSF1R 2762/4885POLB 2944/4885CYP2C9 4827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.